lung cancer news from FiercePharma
NewsBMS swallows Canada's Erbitux price
Call it a new pricing strategy. Bristol-Myers Squibb is preparing to launch the cancer treatment Erbitux in Canada after a two-year wrangle over cost. Approved by Health Canada in September 2005, Read more...
SPOTLIGHT: NICE rejects Roche drug as too costly
Roche's lung cancer med Tarceva got the goodbye gong from the U.K.'s National Institute for Clinical Excellence, which ruled that the drug wasn't a cost-effective option for treating non-small cell Read more...
Stanley: Erbitux outperformed Avastin
Morgan Stanley got a juicy scoop on the Avastin versus Erbitux boxing match: Genentech's Avastin faces news that as-yet-unpublished data shows Erbitux delivering an "unexpected survival Read more...
Roche, Cipla trade jabs on Tarceva
We turn to India for updates on another cancer-drug battle, this one between Roche's brand-name Tarceva and Cipla's copycat version, Erlocip. A Roche distributor tattled to India's Drug Controller Read more...
What Exubera says about safety
When Pfizer announced yesterday that the inhaled insulin product it spiked last fall may have triggered lung cancer in a few patients, pundits immediately pronounced the death of all insulin Read more...
Court sends Mircera case to ITC
Another chapter in what's becoming a long Mircera saga: A federal appeals court ruled that Roche could import the anemia drug so long as it wasn't for sale--but sent the case back to the Read more...
High-priced meds spur dosing debate
What's a drug worth? In the case of Cerezyme, a remedy for a rare inherited enzyme deficiency known as Gaucher disease, the answer is $300,000 a year. But experts are questioning whether lower doses Read more...
Bayer loses Yasmin patent fight
Bayer had the Yasmin rug pulled out from under it yesterday. A U.S. court voided the contraceptive's key patent, leading the German conglomerate to revise its 2008 profit expectations Read more...
Bayer lower 2008 expectations
Call it Bad News Bayer. The German company reported a whopping 78 percent drop in profits for the fourth quarter and forecast 2008 sales growth at its lowest level in years. Though 2007 full-year Read more...
ALSO NOTED: MedImmune acquisition could pay dividends; Sun challenges J&J patent;
> Analysts say AstraZeneca's buyout of MedImmune could pay extra dividends as health officials expand their recommendations for an flu jab to all children between the ages of six months and 18. Read more...
| Press ReleasesPRESS RELEASE: ImClone's ERBITUX Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study ImClone's ERBITUX Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study; Shares Soar NEW YORK -- ImClone Systems Incorporated and Bristol-Myers Squibb Company (NYSE: BMY - Read more... |
Get more lung cancer coverage at:
Paid Research Reports
- Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
- Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response
- Biotech 2008 – life sciences industry report (online & print)
- Is there a market for alcoholism pharmacotherapies?
- New report provides Rheumatoid Arthritis market insight